Surgery is the cornerstone of ovarian cancer treatment and the single strongest predictor of long-term survival. Whether the cancer is caught early or found at an advanced stage, the type and completeness of the operation shapes outcomes more than almost any other variable. The specific procedures involved range from a relatively straightforward staging operation to multi-organ resections that can last many hours, and the right approach depends on the stage of disease, how the cancer responds to chemotherapy, and whether the surgeon can remove all visible tumor. Understanding what each type of surgery aims to accomplish, and when one strategy is chosen over another, helps patients and families navigate a landscape that can feel overwhelming.
Why Completeness of Surgery Matters So Much
The overriding goal in ovarian cancer surgery is to leave behind no visible tumor, a result surgeons call “no gross residual disease.” A nationwide Norwegian study found that patients left with even tiny amounts of residual tumor had roughly two to three times the risk of death compared with those whose surgeons achieved a complete resection, and this held true whether the residual disease measured a few millimeters or several centimeters.1British Journal of Cancer. Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway An earlier study reported a median overall survival of about 86 months after complete removal of all visible disease, dropping to 46 months when small amounts of tumor remained and 37 months when larger deposits were left behind.2PubMed. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer This gap is why surgical teams sometimes perform extensive, multi-organ procedures to chase down every last deposit of tumor. The survival benefit of a complete resection dwarfs many other prognostic factors.
Staging Surgery for Apparently Early Disease
When ovarian cancer appears confined to one or both ovaries at the time of diagnosis, a thorough staging operation is critical to determine whether microscopic disease has already spread. This staging involves inspecting and biopsying multiple sites throughout the abdomen, sampling lymph nodes along the pelvic and para-aortic regions, removing the omentum, and washing the abdominal cavity to check for free-floating cancer cells. Without this comprehensive evaluation, the cancer may be understaged, meaning disease elsewhere in the abdomen goes undetected.
A systematic review and meta-analysis of studies on clinically early-stage ovarian cancer found that about one in five patients was upstaged after a complete surgical staging procedure, with an overall upstaging rate of roughly 19%. High-grade tumors fared much worse: the upstaging rate for high-grade disease was around 41%, meaning nearly half of patients who appeared to have early cancer actually had more advanced disease once every corner of the abdomen was checked.3PubMed. The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis Those hidden deposits change the treatment plan, often requiring chemotherapy that would otherwise be omitted.
Despite how much is at stake, incomplete staging remains common. A European study found that sampling of para-aortic lymph nodes was omitted in 78% of incompletely staged patients, and pelvic lymph node dissection was skipped in over half. Biopsies of the diaphragm were omitted in more than half of cases, and biopsies of different peritoneal surfaces were left out more than a third of the time.4PubMed. Understanding the problem of inadequately staging early ovarian cancer These gaps often occur when surgery is performed by non-specialist surgeons at community hospitals, a theme that recurs throughout ovarian cancer care.
Primary Debulking Versus Chemotherapy First
For women diagnosed with advanced ovarian cancer, there are two broad strategies. The first is primary debulking surgery: going straight to the operating room to remove as much tumor as possible, followed by chemotherapy afterward. The second is neoadjuvant chemotherapy, where three or four cycles of chemotherapy are given first to shrink the tumor, followed by an interval debulking surgery, then more chemotherapy to finish the course.
A landmark trial published in the New England Journal of Medicine compared these two approaches head-to-head in women with bulky stage IIIC or IV ovarian cancer. Survival was statistically equivalent: the hazard ratio for death was 0.98, meaning neither strategy had a meaningful survival edge. However, after neoadjuvant chemotherapy, surgeons were able to reduce the largest remaining tumor to one centimeter or less in about 81% of patients, compared with only 42% after upfront surgery. Complications and postoperative death rates were also lower after interval debulking.5PubMed. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
A later meta-analysis, however, suggested the picture may be more complicated. Pooling data across multiple studies, it found that neoadjuvant chemotherapy was associated with modestly shorter overall survival compared with primary surgery. At the same time, neoadjuvant chemotherapy was linked to substantially lower rates of postoperative death and major infection.6PubMed Central. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis The current consensus among most gynecologic oncologists is that upfront surgery is preferred when the surgical team believes complete resection is achievable, but neoadjuvant chemotherapy is the better option when extensive disease makes upfront complete removal unlikely or when the patient’s overall health would not tolerate a major initial operation.
Heated Chemotherapy Delivered During Surgery
Hyperthermic intraperitoneal chemotherapy, commonly called HIPEC, involves bathing the open abdominal cavity in heated chemotherapy solution immediately after the surgeon has removed all visible tumor. The heat increases the penetration and killing power of the drugs against any microscopic cancer cells remaining on peritoneal surfaces.
A systematic review and meta-analysis of randomized trials found that adding HIPEC to interval cytoreductive surgery significantly improved five-year overall survival, with a 23% relative reduction in risk of death, along with meaningfully longer disease-free survival.7PubMed Central. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials A separate study comparing interval surgery with and without HIPEC found that median progression-free survival nearly doubled in the HIPEC group, reaching about 23 months versus 14 months, and the rate of peritoneal recurrence was cut roughly in half. The frequency of serious postoperative complications was similar in both groups, at around 3%.8JAMA Surgery. Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy
HIPEC is not universally adopted. It adds operative time, requires specialized equipment and training, and not every trial has shown an identical benefit. Some centers reserve it for the interval-debulking setting, where the strongest evidence exists, while others offer it at the time of primary debulking as well. The technique appears most beneficial when surgeons can first achieve a complete resection, since bathing a field full of remaining tumor in chemotherapy is far less effective than treating a clean surgical bed.
The Lymph Node Question
Whether to remove lymph nodes during advanced ovarian cancer surgery has been debated for years. In early-stage disease, lymph node sampling is a core part of staging, as described above. But for patients with advanced disease who have no clinically suspicious lymph nodes, the picture changed significantly with the LION trial. That large randomized study found that systematic removal of pelvic and para-aortic lymph nodes offered no survival benefit whatsoever in patients with advanced ovarian cancer who had undergone successful debulking. Median overall survival was about 69 months in both the lymphadenectomy and no-lymphadenectomy groups. Worse, the lymphadenectomy group experienced more serious complications: the rate of repeat surgery was roughly double, and 60-day postoperative mortality was over three times higher.9PubMed. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
The LION trial specifically enrolled patients whose lymph nodes appeared normal before and during surgery. A separate study of patients undergoing primary debulking found that lymphadenectomy was associated with longer survival after recurrence, particularly in patients who had minimal residual disease after surgery.10PubMed. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis So the decision is nuanced: removing clinically normal nodes in advanced disease adds risk without benefit, but removing bulky or suspicious nodes as part of debulking is standard practice.
For early-stage disease, researchers are investigating sentinel lymph node mapping as a less invasive alternative to full lymph node dissection. The concept, borrowed from breast cancer and melanoma surgery, involves injecting a tracer near the tumor and identifying the first lymph nodes that drain from that area. A review of studies involving over 200 patients found an overall sentinel node detection rate of about 85%, though results varied widely between centers.11PubMed Central. Where are we going with sentinel nodes mapping in ovarian cancer? A prospective multicenter study reported a lower detection rate of 58%, and among patients with positive nodes whose sentinel node was successfully mapped, three cases were missed, yielding a sensitivity of about 79%.12Journal of Clinical Oncology. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage ovarian cancer: A prospective multicentre study (SELLY) Sentinel node mapping for ovarian cancer remains experimental, and the technique needs refinement before it can replace standard staging lymphadenectomy.
Extending Surgery Into the Upper Abdomen
Advanced ovarian cancer frequently spreads to the upper abdomen, with the diaphragm being an especially common site. Surgeons who are comfortable operating in this region can strip tumor off the diaphragm surfaces, mobilize the liver to access disease behind it, and when necessary, remove the spleen or part of the pancreas.13PubMed. Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy In a series of patients undergoing these upper abdominal procedures, surgeons achieved no visible residual disease in about 88% of cases.14PubMed Central. Right Upper Abdominal Resections in Advanced Stage Ovarian Cancer
These operations demand specialized skill and carry their own risks, including pleural effusion, diaphragm injury, and bleeding. But the alternative, leaving tumor behind in the upper abdomen because the surgeon is not trained to operate there, directly undermines the completeness of resection that drives survival. This is one of the main reasons treatment at a specialized center matters.
Minimally Invasive Surgery in Select Cases
Open surgery through a large abdominal incision has been the standard approach for ovarian cancer, and for many patients with bulky advanced disease, it remains necessary. However, laparoscopic surgery is gaining traction in carefully selected situations, particularly for interval debulking after a good response to neoadjuvant chemotherapy.
A systematic review and meta-analysis comparing laparoscopic and open interval debulking found that minimally invasive surgery achieved complete resection to no visible tumor more often, with about half the complication rate, less blood loss, shorter hospital stays, and faster initiation of adjuvant chemotherapy afterward. Overall survival was statistically similar between the two approaches.15PubMed Central. Outcome After Laparoscopic Compared to Open Interval Debulking Surgery for Advanced Stage Ovarian Cancer: A Systematic Review and Meta-Analysis A separate retrospective cohort study of primary laparoscopic cytoreduction reported similar feasibility in strictly selected patients, with a conversion-to-open rate of only about 3% and satisfactory cytoreduction rates approaching 95%.16PubMed Central. Feasibility and outcome of primary laparoscopic cytoreductive surgery for advanced epithelial ovarian cancer: a comparison to laparotomic surgery in retrospective cohorts
Patient selection is the key phrase here. Laparoscopic surgery works best when the tumor burden has been substantially reduced by chemotherapy and the disease distribution is favorable. It is not a replacement for the aggressive open operations that many patients with advanced disease need.
Surgery When Cancer Comes Back
Ovarian cancer recurs in the majority of women with advanced disease, and whether to operate a second time is a critical decision. Two of three major randomized trials on secondary cytoreductive surgery have shown a survival benefit when surgeons can achieve complete removal of all visible recurrent disease. Incomplete removal, on the other hand, was associated with worse survival than chemotherapy alone.17PubMed Central. The current role of secondary cytoreductive surgery for recurrent ovarian cancer
A meta-analysis reinforced this pattern: complete resection at secondary surgery was associated with roughly 40-45% reductions in the risk of disease progression and death compared with chemotherapy alone, while incomplete resection offered no survival benefit at all.18PubMed Central. The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis The practical implication is that patient selection tools, which aim to predict whether complete resection is achievable before committing to the operation, are essential for deciding who benefits from repeat surgery.
Predicting Whether Surgery Will Succeed
Before opening the abdomen, surgical teams need an estimate of how much disease they will find and whether complete resection is realistic. Several scoring systems have been developed for this purpose, with the Peritoneal Cancer Index and the Predictive Index Value being the most widely studied. A systematic review found that these tools showed moderate to good accuracy, but because different studies used different cutoff values, no single scoring system emerged as clearly best.19PubMed. Peroperative scoring systems for predicting the outcome of cytoreductive surgery in advanced-stage ovarian cancer – A systematic review
CT-based prediction models, which evaluate disease distribution on imaging before surgery, have shown promising accuracy. One study evaluating CT-based versions of these scoring systems reported that a Predictive Index score of three or higher correctly identified all patients in whom complete surgery was not achievable, with overall accuracy around 80%.20International Journal of Gynecological Cancer. Computed tomography–based prediction of interval cytoreduction in advanced ovarian cancer Diagnostic laparoscopy, where a camera is inserted through a small incision to directly visualize the tumor burden before committing to a full operation, is also widely used and allows surgeons to abort procedures unlikely to achieve a complete result.
Frozen Section Analysis During Surgery
When the nature of an ovarian mass is uncertain, surgeons rely on intraoperative frozen section analysis, in which a pathologist rapidly examines tissue while the patient is still on the operating table. The result determines whether the surgeon proceeds with a cancer operation or a more conservative approach. A Cochrane review of this technique found that frozen section correctly identified invasive cancer about 90% of the time, with a specificity above 99%, meaning false positives were extremely rare.21Cochrane Database of Systematic Reviews. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses
The weak spot is borderline tumors, which sit between benign and malignant. Multiple studies have reported that frozen section catches borderline tumors only about half to three-quarters of the time.22PubMed Central. Role of Frozen Section in Surgical Management of Ovarian Neoplasm23Medical Journal Armed Forces India. Diagnostic accuracy of frozen section in ovarian masses: A single centre study A borderline result on frozen section sometimes turns out to be cancer on the final pathology report days later, which may require a second operation to complete the staging. Patients should be counseled before surgery that a definitive answer may not always come while they are still in the operating room.
Fertility-Sparing Approaches for Young Women
Standard ovarian cancer surgery removes both ovaries, the uterus, and the fallopian tubes, which permanently ends fertility. For young women with early-stage, low-grade disease who want to have children, fertility-sparing surgery preserves the unaffected ovary and the uterus while removing only the cancerous ovary along with full staging.
A Swedish nationwide prospective study found that fertility-sparing surgery in early-stage disease had a five-year overall survival rate of 92%, with no statistical difference in survival compared with women who had the standard radical operation. Recurrences were actually less common in the fertility-sparing group (6% versus 13%), likely reflecting careful patient selection. Nine women in the fertility-sparing group went on to give birth to 12 healthy children.24PubMed Central. A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women Fertility-sparing surgery is generally considered safe for patients with stage IA to IC, grade 1 or 2 disease.25PubMed. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes
The approach carries clear risks in the wrong setting. A registry-based study found that fertility-sparing surgery was associated with significantly worse survival among women with advanced-stage serous ovarian cancer.26PubMed Central. Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries The message is clear: this approach is safe only when the cancer meets strict criteria for stage, grade, and histology. Completion surgery to remove the remaining ovary and uterus is recommended once childbearing is complete.
Recovery and Enhanced Recovery Protocols
Ovarian cancer surgery, particularly the extensive cytoreductive procedures, carries significant recovery demands. Enhanced recovery after surgery (ERAS) protocols bundle multiple perioperative improvements together: shorter preoperative fasting, optimized fluid management, early mobilization, multimodal pain control, and early resumption of eating. A randomized trial in patients undergoing complex ovarian cancer surgery found that ERAS reduced the median hospital stay by two days (seven versus nine days) and cut the readmission rate from 20% to 6%, without increasing complications or mortality.27PubMed. PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery
A prospective cohort study of ERAS implementation showed that preoperative fasting for fluids dropped from a median of 11 hours to under 4 hours, and intraoperative fluid administration was significantly reduced, both changes associated with fewer metabolic disturbances and faster gut recovery.28International Journal of Gynecological Cancer. Implementation of enhanced recovery after surgery pathways in gynecologic oncology: a prospective cohort study ERAS adoption in ovarian cancer has been slower than in some other surgical specialties because of the uniquely variable complexity of these operations, but the evidence increasingly supports making it standard practice.29PubMed Central. The implementation of enhanced recovery after surgery protocols in ovarian malignancy surgery
Where You Have Surgery Matters
Hospital volume and surgeon subspecialization are among the most consistent predictors of ovarian cancer survival. A nationwide study found that treatment at high-volume hospitals was associated with a 21% reduction in mortality risk compared with low-volume hospitals, and this advantage held for both early and advanced disease. Location in a major city versus a smaller region made no difference once volume was accounted for.30PubMed Central. Volume over location: prioritizing case volume over regional distribution in ovarian cancer treatment
Surgeon specialty matters just as much. A study comparing outcomes by surgeon type found that five-year survival for early-stage disease was 86% when a gynecologic oncologist performed the surgery versus 70% with a general gynecologist. For advanced disease, the gap was 21% versus 13%.31PubMed. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma The difference reflects everything discussed in this article: subspecialists are more likely to perform comprehensive staging, achieve complete cytoreduction, operate in the upper abdomen when needed, and manage the perioperative care optimally. If you or someone you know faces ovarian cancer surgery, seeking care at a high-volume center with a gynecologic oncology team is one of the most impactful decisions you can make.
Palliative Surgery for Bowel Obstruction
In the later stages of recurrent ovarian cancer, bowel obstruction becomes a common and distressing complication as tumor masses compress or block the intestines. The decision to operate in this setting is fraught: the cancer is not curable, the patient is often frail, and the surgery carries real risks. A meta-analysis of surgical versus nonsurgical management of malignant bowel obstruction in ovarian cancer found that surgery provided a higher rate of symptom relief and meaningfully longer survival. However, the 30-day mortality rate was higher in the surgical group.32PubMed. Palliative treatment for bowel obstruction in ovarian cancer: a meta-analysis Procedures may involve removing the blocked segment, creating a bypass around the obstruction, or placing a stoma to divert the intestinal contents. The choice between surgery and conservative management with medications, intravenous fluids, and sometimes stenting depends heavily on the patient’s overall condition, the number of obstruction points, and her goals of care.
Emerging Tools in the Operating Room
One of the persistent challenges in cytoreductive surgery is that small tumor deposits, particularly those under a few millimeters, can be nearly invisible to the naked eye. Intraoperative fluorescence imaging is being developed to address this gap. Fluorescent tracers administered to the patient bind to tumor cells and glow under special light, allowing the surgeon to see deposits that would otherwise be missed.33PubMed. Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery Several agents targeting the folate receptor, which is overexpressed on many ovarian cancers, are in clinical trials. The technology is promising but not yet part of routine practice; its ultimate value will depend on whether highlighting more tumor deposits actually translates into more complete resections and better survival. For now, the surgeon’s eyes, hands, and experience remain the primary tools, which circles back to why high-volume, subspecialized surgical teams consistently deliver the best results.